Scholarlink

<p>Globally, breast cancer remains a leading cause of morbidity in women. Conventional therapies, including surgical intervention, radiation, and chemical treatments, though effective, frequently result in significant adverse effects and toxicity. CAR-T cell therapy represents a novel immunotherapeutic strategy, wherein T cells are genetically modified to precisely target and eradicate malignant cells. The article provides a detailed introduction to the structure and function of CAR-T cells, particularly the improvements in anti-tumor efficacy across different generations of CAR-T cells. Furthermore, the article explores the primary targets of CAR-T cell therapy in the clinical treatment of breast cancer, such as HER2, EGFR, and MUC1, and analyzes the potential and limitations of these targets in therapy. In conclusion, the review outlines significant hurdles in CAR-T cell therapy for breast cancer, such as tumor diversity, the inhibitory tumor milieu, unintended targeting, and cytokine storm, offering strategic solutions to mitigate these obstacles.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application

  • 期刊论文

  • 发表日期：

    2026年6月30日

查看全文
  • Honghao Yu,
  • Wenzhi Feng,
  • Di Lan,
  • Qianyi Liu,
  • Xia He,
  • Siyu Zhang,
  • Chunyu Tong,
  • Bocui Song

摘要

Globally, breast cancer remains a leading cause of morbidity in women. Conventional therapies, including surgical intervention, radiation, and chemical treatments, though effective, frequently result in significant adverse effects and toxicity. CAR-T cell therapy represents a novel immunotherapeutic strategy, wherein T cells are genetically modified to precisely target and eradicate malignant cells. The article provides a detailed introduction to the structure and function of CAR-T cells, particularly the improvements in anti-tumor efficacy across different generations of CAR-T cells. Furthermore, the article explores the primary targets of CAR-T cell therapy in the clinical treatment of breast cancer, such as HER2, EGFR, and MUC1, and analyzes the potential and limitations of these targets in therapy. In conclusion, the review outlines significant hurdles in CAR-T cell therapy for breast cancer, such as tumor diversity, the inhibitory tumor milieu, unintended targeting, and cytokine storm, offering strategic solutions to mitigate these obstacles.